S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.45 (-4.20%)
BABA   84.11 (-1.90%)
AMD   96.11 (-4.22%)
T   15.31 (-1.54%)
F   12.20 (-1.29%)
MU   67.90 (-2.55%)
CGC   0.77 (-12.02%)
GE   112.99 (-1.62%)
DIS   82.73 (+0.21%)
AMC   7.70 (-5.64%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:CERE

Cerevel Therapeutics (CERE) Competitors

$20.63
-0.17 (-0.82%)
(As of 05:18 PM ET)
Compare
Today's Range
$20.48
▼
$21.15
50-Day Range
$20.55
▼
$30.73
52-Week Range
$20.48
▼
$35.98
Volume
772,478 shs
Average Volume
613,015 shs
Market Capitalization
$3.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.40
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media

CERE vs. MLTX, FOLD, IMGN, INSM, AXSM, CORT, CYTK, EVO, MDGL, and BPMC

Should you be buying Cerevel Therapeutics stock or one of its competitors? The main competitors of Cerevel Therapeutics include MoonLake Immunotherapeutics (MLTX), Amicus Therapeutics (FOLD), ImmunoGen (IMGN), Insmed (INSM), Axsome Therapeutics (AXSM), Corcept Therapeutics (CORT), Cytokinetics (CYTK), Evotec (EVO), Madrigal Pharmaceuticals (MDGL), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.

Cerevel Therapeutics vs.

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

MoonLake Immunotherapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

MoonLake Immunotherapeutics presently has a consensus price target of $58.80, suggesting a potential upside of 10.57%. Cerevel Therapeutics has a consensus price target of $34.00, suggesting a potential upside of 64.81%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe Cerevel Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MoonLake Immunotherapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
Cerevel Therapeutics
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60

87.7% of Cerevel Therapeutics shares are owned by institutional investors. 15.3% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cerevel Therapeutics' return on equity of -23.18% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MoonLake ImmunotherapeuticsN/A -23.18% -22.26%
Cerevel Therapeutics N/A -83.19%-40.30%

Cerevel Therapeutics received 129 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. Likewise, 68.61% of users gave Cerevel Therapeutics an outperform vote while only 64.86% of users gave MoonLake Immunotherapeutics an outperform vote.

CompanyUnderperformOutperform
MoonLake ImmunotherapeuticsOutperform Votes
24
64.86%
Underperform Votes
13
35.14%
Cerevel TherapeuticsOutperform Votes
153
68.61%
Underperform Votes
70
31.39%

In the previous week, MoonLake Immunotherapeutics had 9 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 10 mentions for MoonLake Immunotherapeutics and 1 mentions for Cerevel Therapeutics. Cerevel Therapeutics' average media sentiment score of -0.15 beat MoonLake Immunotherapeutics' score of -1.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
MoonLake Immunotherapeutics Neutral
Cerevel Therapeutics Negative

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Cerevel Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MoonLake ImmunotherapeuticsN/AN/A-$49.97M-$1.04-51.13
Cerevel TherapeuticsN/AN/A-$351.51M-$2.55-8.09

Summary

MoonLake Immunotherapeutics beats Cerevel Therapeutics on 10 of the 15 factors compared between the two stocks.


Get Cerevel Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CERE vs. The Competition

Export to Excel
MetricCerevel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.25B$5.13B$4.29B$6.26B
Dividend YieldN/A2.64%2.49%5.88%
P/E Ratio-8.094.44124.2112.18
Price / SalesN/A156.062,877.6469.13
Price / CashN/A20.7386.79101.50
Price / Book6.203.723.724.71
Net Income-$351.51M$178.51M$121.24M$185.55M
7 Day Performance-7.61%-5.08%-2.07%-3.23%
1 Month Performance-4.67%-5.94%-0.80%-4.29%
1 Year Performance-22.71%2.65%5.29%1.42%

Cerevel Therapeutics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLTX
MoonLake Immunotherapeutics
1.982 of 5 stars		$57.82
+9.9%		$58.80
+1.7%		+676.2%$3.61BN/A-55.6020Analyst Report
Gap Up
High Trading Volume
FOLD
Amicus Therapeutics
1.738 of 5 stars		$13.33
+0.3%		$15.20
+14.0%		+13.3%$3.83B$350.56M-20.83484News Coverage
IMGN
ImmunoGen
2.5034 of 5 stars		$15.45
-1.4%		$21.25
+37.5%		+190.4%$3.85B$189.56M-21.46277Insider Selling
INSM
Insmed
2.231 of 5 stars		$26.93
+1.6%		$43.71
+62.3%		+7.3%$3.87B$269.47M-5.13373Analyst Report
Short Interest ↑
News Coverage
AXSM
Axsome Therapeutics
2.731 of 5 stars		$82.21
+2.0%		$103.25
+25.6%		+26.8%$3.88B$50.04M-19.21422News Coverage
CORT
Corcept Therapeutics
1.8394 of 5 stars		$33.03
0.0%		$30.81
-6.7%		+26.2%$3.39B$401.86M39.80299Insider Selling
Analyst Revision
CYTK
Cytokinetics
2.386 of 5 stars		$35.05
+0.9%		$58.21
+66.1%		-39.7%$3.36B$9.95M-6.16409
EVO
Evotec
1.7006 of 5 stars		$11.56
-0.9%		$14.00
+21.1%		N/A$4.09B$798.41M0.004,952Gap Down
MDGL
Madrigal Pharmaceuticals
2.5371 of 5 stars		$176.87
-4.4%		$309.18
+74.8%		+147.8%$3.27BN/A-9.4892Analyst Report
News Coverage
BPMC
Blueprint Medicines
1.976 of 5 stars		$52.81
-1.4%		$76.20
+44.3%		-28.0%$3.20B$204.04M-5.73660Positive News

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:CERE) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -